Longhorn Vaccines and Diagnostics to Present Data on Mycobacterium Tuberculosis Vaccine Candidate, LHNVD-301, at The Union World Conference on Lung Health 2023

2023-11-02

疫苗

The unconjugated peptide-based vaccine combines a targeted approach to tuberculosis and antimicrobial resistant virus strains BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)-- Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023. The ePoster will be presented as a part of TBScience 2023, a dedicated event focused on basic and translational tuberculosis (TB) research. The Conference will take place in Paris on November 15-18, 2023. LHNVD-301 is an unconjugated, peptide-based vaccine that combines Mycobacterium tuberculosis heat shock protein and Peptidoglycan to generate broad reactive antibodies. The vaccine and the monoclonal antibodies they produce are in development to combat antimicrobial resistant strains of tuberculosis and gram-positive bacteria, which are a global threat to public health. Abstract Title: Unconjugated Peptides Comprising Mycobacterium tuberculosis Heat Shock Protein and Staphylococcus aureus Peptidoglycan Generate Broadly Reactive Antibodies to Gram-positive Bacteria Abstract Number: 3517 Presenter: Nimisha Rikhi, PhD., Research Scientist, Microbiology and Immunology Laboratory, Longhorn Vaccines and Diagnostics ePoster Session Title: TB within the Global AMR fight: preventing drug resistance Session Date: 15 November, 2023 Over the last 53 years, the Union World Conference on Lung Health has presented the latest scientific research in all aspects of lung health, including implementation of evidence-based health policies and decisions. For more information about Longhorn, visit . About Longhorn Vaccines and Diagnostics Longhorn Vaccines and Diagnostics LLC is a closely held One Health company based in Maryland that is developing vaccines and diagnostic tools for worldwide public health concerns and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn caters to both in order to surveil, diagnose, prevent and treat the next infectious disease. Longhorn developed and patented a composite peptide platform for generating vaccines against challenging pathogens, multiple pathogens, and engineering multiple targets for preventing the effects of a disease. LHNVD-105, an adjuvated universal influenza vaccine targeting NA, M1, M2, M2e, HA head and HA stalk, is Longhorn’s lead vaccine candidate. An IND-enabling stage vaccine, LHNVD-105 is expected to enter phase I clinical trials in Q2/Q3 2024. Longhorn has multiple vaccines and monoclonal antibody candidates in pre-clinical testing for viral and respiratory diseases. View source version on businesswire.com: Contacts Longhorn Vaccines and Diagnostics LLC Jeffrey Fischer Email: jeff@lhnvd.com Media Alexis Feinberg – ICR Westwicke PR Email: alexis.feinberg@westwicke.com Investor Relations Stephanie Carrington – ICR Westwicke IR Email: stephanie.carrington@westwicke.com Source: Longhorn Vaccines and Diagnostics LLC View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构